Acylamino-substituted cyclic carboxylic acid derivatives and their use as pharmaceuticals

A compound of formula I,

• wherein
• ring A is a 5- or 6-membered carbocyclic ring, which is saturated or comprises 1 double bond, wherein ring A is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, R1, R2, (C2-C6)-alkenyl, HO—, R1—O—, phenyl-(C1-C4)-alkyl-O—, R1—C(O)—O—, R1—S(O)2—O—, R1—S(O)m—, H2N—, R1—NH—, R1—N(R1)—, R1—C(O)—NH—, R1—C(O)—N(R1)—, R1—S(O)2—NH—, R1—S(O)2—N(R1)—, R1—C(O)—, HO—C(O)—, R1—O—C(O)—, H2N—C(O)—, R1—NH—C(O)—, R1—N(R1)—C(O)—, H2N—S(O)2—, R1—NH—S(O)2—, R1—N(R1)—S(O)2—, F5S—, NC—, oxo and methylene;
• Y is chosen from the series consisting of N(R10), O, N═C(R14) and C(R15)═N;
• Z is chosen from the series consisting of N and C(R16);
• R0 is chosen from the series consisting of hydrogen and R1;
• R1 is chosen from the series consisting of (C1-C6)-alkyl, (C3-C7)-cycloalkyl and (C3-C7)-cycloalkyl-(C1-C4)-alkyl-;
• R2 is (C1-C4)-alkyl which is substituted by one or more identical or different substituents chosen from the series consisting of HO— and (C1-C4)-alkyl-O—;
• R10 is chosen from the series consisting of hydrogen and R11;
• R11, R30, R33, R35, R54, R55, R57 and R58 and R58 are, independently of each other group R11, R30, R33, R35, R54, R55, R57 and R58, chosen from the series consisting of (C1-C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, (C3-C7)-cycloalkyl and (C3-C7)-cycloalkyl-(C1-C4)-alkyl- which are all optionally substituted by one or more identical or different substituents R70;
• R12, R13, R14, R15 and R16 are independently of each other chosen from the series consisting of hydrogen, halogen, (C1-C4)-alkyl, HO—(C1-C4)-alkyl-, (C1-C4)-alkyl-O—, (C1-C4)-alkyl-S(O)m—, H2N—, (C1-C4)-alkyl-NH—, (C1-C4)-alkyl-N((C1-C4)-alkyl-, (C1-C4)-alkyl-C(O)—and NC—, or R13 or R14, together with the one of the groups R21 and R22 which is not the group of the formula II, forms a chain consisting of 3 to 5 chain members of which 0, 1 or 2 chain members are identical or different hetero chain members chosen from the series consisting of N(R17), O and S, but two hetero chain members cannot be present in adjacent positions, and the other chain members are identical or different groups C(R18)(R18);
• R17 and R25 are independently of each other chosen from the series consisting of hydrogen and (C1-C4)-alkyl;
• R18, independently of each other group R18, is chosen from the series consisting of hydrogen, fluorine and (C1-C4)-alkyl, or two of the groups R18 bonded to the same carbon atom, together with the carbon atom carrying them, form a 3-membered to 6-membered cycloalkane ring which is optionally substituted by one more identical or different substituents chosen from the series consisting of fluorine and (C1-C4)-alkyl;
• R20 is chosen from the series consisting of hydrogen and (C1-C4)-alkyl;
• one of the groups R21 and R22 is a group of the formula II
• R24—R23— II
• and the other of the groups R21 and R22 is chosen from the series consisting of hydrogen, halogen, R30, HO—, R30—O—, R30—C(O)—O—, R30—S(O)2—O—, R30—S(O)m—, H2N—, R30—NH—, R30—N(R30)—, R30—C(O)—NH—, R30—C(O)—N(R71)—, R30—S(O)2—NH—, R30—S(O)2—N(R71)—, R30—C(O)—, HO—C(O)—, R30—O—C(O)—, H2N—C(O)—, R30—NH—C(O)—, R30—N(R30)—C(O)—, H2N—S(O)2—, R30—NH—S(O)2—, R30—N(R30)—S(O)2—, NC—, O2N— and Het1, or together with R13 or R14 forms a chain as specified in the definition of R13 and R14;
• R23 is a direct bond or a chain consisting of 1 to 5 chain members of which 0, 1 or 2 chain members are identical or different hetero chain members chosen from the series consisting of N(R25), O, S, S(O) and S(O)2, but two hetero chain members can be present in adjacent positions only if one of them is chosen from the series consisting of S(O) and S(O)2 and the other is chosen from the series consisting of N(R25), O and S, and the other chain members are identical or different groups C(R26)(R26);
• R24 is a 3-membered to 10-membered, monocyclic or bicyclic ring, which is saturated and contains 0 or 1 hetero ring members, or is unsaturated and contains 0, 1 or 2 identical or different hetero ring members, wherein the hetero ring members are chosen from the series consisting of N, N(R32), O, S, S(O) and S(O)2, and wherein the ring is optionally substituted on ring carbon atoms by one or more identical or different substituents chosen from the series consisting of halogen, R33, oxetanyl, HO—, R33—O—, R33—C(O)—O—, R33—S(O)2—O—, R33—S(O)m—, H2N—, R33—NH—, R33—N(R33)—, R33—C(O)—NH—, R33—C(O)—N(R71)—, R33—S(O)2—NH—, R33—S(O)2—N(R71)—, H2N—S(O)2—NH—, R33—NH—S(O)2—NH—, R33—N(R33)—S(O)2—NH—, H2N—S(O)2—N(R71)—, R33—NH—S(O)2—N(R71)—, R33—N(R33)—S(O)2—N(R71)—, R33—C(O)—, HO—C(O)—, R33—O—C(O)—, H2N—C(O)—, R33—NH—C(O)—, R33—N(R33)—C(O)—, H2N—S(O)2—, R33—NH—S(O)2—, R33—N(R33)—S(O)2—, NC—, O2N— and oxo ;
• R26, independently of each other group R26, is chosen from the series consisting of hydrogen, fluorine, (C1-C4)-alkyl and HO—, or two groups R26 bonded to the same carbon atom together are oxo, or two of the groups R26 or one group R25 and one group R26, together with the comprised chain members, form a 3-membered to 7-membered monocyclic ring which is saturated and contains 0, 1 or 2 identical or different hetero ring members chosen from the series consisting of N, N(R34), O, S, S(O) and S(O)2, which ring is optionally substituted on ring carbon atoms by one more identical or different substituents chosen from the series consisting of fluorine and (C1-C4)-alkyl;
• R32 and R34 are independently of each other chosen from the series consisting of hydrogen, R35, R35—S(O)2—, R35—C(O)—, R35—O—C(O)— and phenyl;
• R50 is chosen from the series consisting of R51—O— and R52—N(R53)—;
• R51 is chosen from the series consisting of hydrogen and R54;
• R52 is chosen from the series consisting of hydrogen, R55, NC— and R56—S(O)2—;
• R53 is chosen from the series consisting of hydrogen and R57;
• R56 is chosen from the series consisting of R58 and phenyl;
• R60, independently of each other group R60, is chosen from the series consisting of hydrogen and (C1-C4)-alkyl;
• R70 is chosen from the series consisting of HO—, R71—O—, R71—C(O)—O—, R71—S(O)m—, H2N—, R71—NH—, R71—N(R71)—, R71—C(O)—NH—, R71—C(O)—N(R71)—, R71—S(O)2—NH—, R71—S(O)2—N(R71)—, HO—C(O)—, R71—O—C(O)—, H2N—C(O)—, R71—NH—C(O)—, R71—N(R71)—C(O)—, H2N—S(O)2—, R71—NH—S(O)2—, R71—N(R71)—S(O)2—and oxo;
• R71, independently of each other group R71, is chosen from (C1-C4)-alkyl, (C3-C4)-cycloalkyl and (C3-C4)-cycloalkyl-(C1-C2)-alkyl-;
• Het1 is a monocyclic 4-membered to 7-membered heterocyclic ring which comprises 1 or 2 identical or different hetero ring members chosen from the series consisting of N, N(R60), O, S, S(O) and S(O)2, which ring is saturated and is optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine and (C1-C4)-alkyl;
• m, independently of each other number m, is an integer chosen from the series consisting of 0, 1 and 2;
• phenyl, independently of each other group phenyl, is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (C1-C4)-alkyl, (C1-C4)-alkyl-O— and NC—, unless specified otherwise;
• cycloalkyl, independently of each other group cycloalkyl, and independently of any other substituents on cycloalkyl, is optionally substituted by one or more identical or different substituents chosen from fluorine and (C1-C4)-alkyl;
• and
• alkyl, alkenyl and alkynyl, independently of each other group alkyl, alkenyl and alkynyl, and independently of any other substituents on alkyl, alkenyl and alkynyl, is optionally substituted by one or more fluorine substituents;
• provided that the compound of the formula I is not 1-[(biphenyl-4-carbonyl)-amino]-cyclohexanecarboxylic acid, 1-[4-(2-pyrrolidin-1-yl-ethoxy)-benzoylamino]-cyclohexanecarboxylic acid, 1-[4-(2-piperidin-1-yl-ethoxy)-benzoylamino]-cyclohexanecarboxylic acid, 1-[4-(2-oxo-pyrrolidin-1-yl)-benzoylamino]-cyclohexanecarboxylic acid, 1-{[4-(2-oxo-pyrrolidin-1-yl)-furan-2-carbonyl]-amino}-cyclohexanecarboxylic acid, 1[4,6-dimethyl-pyrimidin-2-ylsulfanyl)-benzoylamino]-cyclopentanecarboxylic acid ethyl ester, 1-[4-(4-oxo-piperidin-1-yl)-benzoylamino]-cyclopropanecarboxylic acid methyl ester or 1-[2-chloro-4-(3-hydroxy-benzylcarbamoyl)-benzoylamino]-cyclopropanecarboxylic acid;
• or a stereoisomeric form thereof or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof.